| Name | Title | Contact Details |
|---|
EasyPosts best-in-class Shipping APIs provide end-to-end flexibility and more control over parcel shipping and logistics processes for anyone shipping online.
Rev360 delivers RevolutionEHR and suite of practice advancement solutions that empower you to experience more profitability and joy in your eye care practice
Find your bookstore: http://www.bnctextbookrental.com BN College on Twitter: http://www.twitter.com/bncollege BN College on Pinterest: http://www.pinterest.com/bncollege
DRI Holdings Inc. is your 15 year Trusted source for Upgraded Homes in Lancaster and Palmdale, Calif. that focuses on helping Low-Income tenants
Juventas Therapeutics is a private clinical-stage company developing novel therapies for ischemic cardiovascular disease. The company`s lead product` JVS-100` is a non-viral plasmid that encodes for stromal cell-derived factor-1 (SDF-1). SDF-1 has been shown to significantly increase end-organ function following tissue injury by promoting cell survival` recruiting endogenous stem cells to the damaged region` and promoting new blood vessel growth. The SDF-1 repair pathway is well conserved throughout end-organ systems providing the opportunity to impact a broad range of diseases. Target cardiovascular clinical indications address large markets with high unmet medical need and significant market potential. Juventas is currently enrolling multiple clinical trials to test therapy efficacy in heart failure and critical limb ischemia patients.